CleveMed Blogs

Kinesia is a compact patient worn device that was developed to measure and assess the severity of the motor symptoms associated with Parkinson’s, including tremor and bradykinesia. For more information on Parkinson’s, click here. Currently, symptoms are assessed using a subjective rating system called the Unified Parkinson’s Disease Rating Scale, or UPDRS. During a typical exam, patients are instructed to perform a series of motor tasks for evaluating symptoms. While the tasks are completed, a clinician watches and visually assess the symptoms, assigning a 0-4 score based on the severity with 0 being the absence of symptoms and 4 being the most severe.

Because of the subjective nature of the UPDRS, there is definitely room for error. Studies have shown that clinicians can score the same symptom severity differently on different days and different clinician scores can vary for the same severity level. Also, patient’s symptoms can vary greatly throughout the course of a day and a one time clinical visit can not capture these fluctuations. It is important to have a method that objectively and consistently tracks patient’s symptoms at the clinic and at home.

Better tracking of symptoms can be incredibly helpful for Parkinson’s patients. Medication is usually the first method of treating symptoms and there is a fine line between under-medicating a patient which can cause symptoms to still persist, prescribing just the right amount and over-medicating a patient which causes a patient to become dyskinetic, or to have wild involuntary movements.

Kinesia is a device that is worn on the hand of the patient while they complete tasks for assessing tremor and bradykinesia. The device then, using algorithms built into the software, automatically assigns a 0-4 score for the tasks. Kinesia provides a consistent repeatable method for evaluating and scoring symptoms and more objectively track the progression of the disease. The device can also be sent home with a patient and the tasks completed at regular intervals to monitor the fluctuation of the patient’s symptoms. Tracking these fluctuations with Kinesia could assist a clinician in regulating medication time and dosage, leading to increased time without symptoms and less of a risk of under or over medicating.

The latest version of Kinesia was just released in January, so check back regularly for updates on the device being used in the field, current clinical trials and new uses for Kinesia. Ultimately, the hope is to assist in creating an improved quality of life for Parkinson’s patients in the US and around the world.